FIGURE 3.

Triptolide pretreatment or posttreatment further increases Mtb HN878-induced expression of lincRNA-P21 and lncRNA-PACER in MDMs. (A): Graphical summary for the experiments on Mtb HN878 infection of MDMs pre- and post-triptolide treatments. Triptolide pretreatment (B, D): MDMs were pretreated with the indicated concentrations of triptolide for 6 h then infected with Mtb HN878 MOI:2 up to 24 h. DMSO was used as a vector control. Total RNA was extracted and then lincRNA-p21 (B) and lncRNA-PACER (D) expression levels were assessed by RT-qPCR. Triptolide post-treatment (C, E): MDMs were infected with Mtb HN878 MOI:2 for 6 h then treated with the indicated concentrations of triptolide up to 24 h. DMSO was used as a vector control. Total RNA was extracted, and then lincRNA p-21 (C) and lncRNA-PACER (E) expression levels were assessed by RT-qPCR. Relative expression was calculated using the $-\Delta \Delta Ct$ method. *p < 0.05; **p < 0.01; ***p < 0.001.